CD8A and prostate carcinoma: Ardiani et al. [48] treated prostate cancer in mice with a combination of ENZ and a vaccine that targets the Twist antigen (involved in the epithelial-to-mesenchymal transition and metastasis) and increases the functional Twist-specific CD8+ T cells.